As the role of anti-inflammatory medication and the magnitude of its effect are still a matter of debate, we aimed to calculate the proportion and odds of VTE in IBD patients treated with anti-TNFα agents and conventional drugs (CS, immunomodulators [IM], 5-aminosalicylates [5-ASA]), with the hypothesis that biologics are associated with the reduced odds of these events. The gene discussed is TNF; the disease is inflammatory bowel disease.